The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Alnylam Pharmaceuticals Inc’s current trading price is -18.27% away from its 52-week high, while its distance from the 52-week low is 75.24%. The stock’s price range for this period has been between $141.98 and $304.39 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 1.04 million for the day, a number notably higher than the average daily volume of 0.86 million over the last three months.
Alnylam Pharmaceuticals Inc experienced a rather steady stock market performance. The highest value in the past year was recorded at $304.39 on 10/17/24 and the lowest value was $141.98 on 04/25/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Alnylam Pharmaceuticals Inc (ALNY) has experienced a quarterly decline of -10.29% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 32.09B and boasts a workforce of 2100 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 265.76, with a change in price of +5.47. Similarly, Alnylam Pharmaceuticals Inc recorded 874,494 in trading volume during the last 100 days, posting a change of +2.25%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for ALNY stands at 84.27. Similarly, the long-term debt-to-equity ratio is also 80.17.
ALNY Stock Stochastic Average
As of today, Alnylam Pharmaceuticals Inc’s raw stochastic average for the last 50 days stands at 25.40%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 26.60%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 12.06% and 5.98%, respectively.
ALNY Stock Price Performance Analysis
The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. Year to date metric has recorded a gain of 29.98%.However, over the last six months, we can see a weaker performance of 64.87%. Over the last 30 days, the price of ALNY has leaped by -16.09%. And in the last five days, it has fallen by -5.98%.
